International Research Highlight
Immune-checkpoint inhibition (ICI) is an approved treatment approach for both unresectable and completely resected advanced-stage melanoma; however, patients with completely resected stage IV disease have been under-represented in clinical trials to date. In particular, the efficacy of dual PD-1 and CTLA4 ICI in this subgroup is unclear. Now, data from the phase II IMMUNED trial address these knowledge gaps.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Passend zum Thema
Fachsymposium Onkologie/© Pfizer